HPV-T / BGI Group - LARVOL DELTA

THE RELATIONSHIP BETWEEN ANTI-HPV T CELL RESPONSES AND CIN RECURRENCE IN WOMEN LIVING WITH HIV. (IPVC 2025) - "We conclude that the naturally elicited systemic HPV-specific T-cell responses are largely stable in WLHIV even after the elimination of antigen load and do not predict the success of excisional treatment. Their possible contribution to CIN clearance in WLHIV needs to be further investigated to guide HPV therapeutic vaccine strategies."

Clinical • Cervical Cancer • Gynecology • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • CD4 • CD8 • IFNG

LEVERAGING COMPUTATIONAL AI-BASED TOOLS TO DESIGN RATIONAL THERAPEUTIC T CELL-BASED VACCINES FOR HPV (IPVC 2025) - "Leveraging a novel AI-based tool, we developed rational therapeutic HPV T-cell vaccines which induce broad, potent CD8+ T-cell responses to HPV proteins present throughout all stages of HPV disease. This potentially provides an alternative therapeutic modality to clear HPV infection and prevent cervical cancer, especially in high-incidence LMICs."

Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Solid Tumor • CD8 • HLA-A

Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: Anhui Provincial Hospital

New trial • Cervical Cancer • Oncology • Solid Tumor

TCR CDR3 chemical complementarity to HPV epitopes is associated with a better outcome for cervical cancer. (PubMed, Mamm Genome) - "Results indicated increased overall survival probabilities consistently across the three TCR datasets with TCR CDR3 chemical complementarity to the same HPV epitopes, specifically immune epitope database (IEDB) designations: IEDB-1625373, IEDB-174148, and IEDB-110943. Among other potential applications of these results, the results may indicate HPV epitopes that could be useful targets for immunotherapy."

Journal • Cervical Cancer • Oncology • Solid Tumor

Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (ASCO 2024) - P2 | "Therefore, exogenous HPV antigens were not necessary to induce anti-HPV T cell responses. Administration of immune-enhancing adjuvant alone is sufficient for inducing anti-HPV immune responses. Consistent systemic decrease in RANTES/CCL5 was demonstrated suggesting possible mechanism in which Candida works through reducing RANTES/CCL5."

Clinical • IO biomarker • P2 data • Cervical Cancer • Dermatology • Gynecology • Oncology • IL12A

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector. (PubMed, NPJ Vaccines) - "Here, we first established that anti-vector immunity induced by Lenti-HPV-07 prime has no impact on the efficacy of a homologous boost to amplify anti-HPV T-cell immunity. We then demonstrated that the effector functions of such Lenti-HPV-07-induced T cells synergize with anti-checkpoint inhibitory treatments by systemic administration of anti-TIM3 or anti-NKG2A monoclonal antibodies. While Lenti-HPV-07 is about to enter a Phase I/IIa clinical trial, these results will help better elucidate its mode of action in immunotherapy against established HPV-mediated malignancies."

Journal • Viral vector • Oncology • CD8 • KLRC1

The immune microenvironment of cancer of the uterine cervix. (PubMed, Histol Histopathol) - "While HPV T-cell responses exist, the tumor seems to evade the immune system upon its tolerance...Therefore, novel biomarkers governing prognosis and treatment planning must be developed, with several studies tackling the significance of the tumor microenvironment in the genesis, development, proliferation, and overall response of cervical cancer during neoplastic processes. This review aims to analyze and contemplate the characteristics of the tumor microenvironment and its role in prognosis, progression, evasion, and invasion, including therapeutic outcome and overall survival."

Journal • Review • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor • Uterine Cancer

Preferential Expansion of HPV16 E1-Specific T Cells from Healthy Donors' PBMCs after Ex Vivo Immunization with an E1E2E6E7 Fusion Antigen. (PubMed, Cancers (Basel)) - "Therapeutic HPV vaccines in clinical development show great promise in improving outcomes for patients who mount an anti-HPV T-cell response; however, far from all patients elicit a sufficient immunological response...We suggest that this assay can be a valuable translational tool to complement the known animal models, not only for HPV therapeutic vaccines, and supports the use of E1 as an immunotherapeutic target. Nevertheless, the findings reported here need to be validated in a larger number of donors and preferably in patient samples."

Journal • Preclinical • Head and Neck Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Oropharyngeal Cancer • Solid Tumor • TRIP13

HPV Prevention Policy Atlas Europe - Tracking Government Policies In Europe On Access To HPV Vaccination, Screening And Information (ESGO 2023) - "Online state information on HPVIt does not reflect the prevalence rate of cervical cancer in the countries... Belgium, Denmark, Ireland and the UK are the policy champions and lead the Atlas with excellent policies on primary secondary prevention and providing evidence based information to citizens.Belarus and Azerbaijan score the worse, as there is literally no information about the HPV prevention to be found and policies on primary or secondary prevention are non-existent. Conclusion The situation in Europe is very unequal. There is a clear divide between northern Europe, Southern Europe and Eastern Europe."

Cervical Cancer • Oncology • Solid Tumor

Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines. (PubMed, Cells) - "In conclusion, we successfully established two humanized mouse models that exhibited strong antigen-specific responses and demonstrated tumor regression following vaccination. These models serve as valuable platforms for assessing the efficacy of therapeutic cancer vaccines targeting HPV16-dysplastic skin and diverse tumor antigens specifically delivered to CD141 DCs."

Journal • Preclinical • Breast Cancer • Graft versus Host Disease • Immunology • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • FLT3 • HLA-A

"Tiedän kor.rokotevaurioryhmistä, että rokotehaitan saaneilla on ollut aktivoitunutta hpv:tä, koska immuniteetti on ’romahtanut’ rokott. aiheuttam. kehon tulehduksen myötä. Vesirokko- ja herpesvirusten aktivoitumista myös. Meilläkin noita vasta-aineita lääkärit otattaneet." (@mrsflower70)

"Suomessahan tytöt on pitkään rokotettu HPV:tä vastaan ja nyt rokotetaan myös pojat. Riittääköhän se suojaksi?" (@PirtaHotulainen)

GI-HPVT-01: HPV-T in HPV-16 Positive Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: BGI, China

Metastases • New P1 trial • Oncology • Solid Tumor